Osmotica Pharmaceuticals Announces $ 35 Million Price

BRIDGEWATER, NJ, 07 Oct 2021 (GLOBE NEWSWIRE) – Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the price of its subscribed public offering previously announced 14,000,000 common shares of the Company and warrants to purchase up to 14,000,000 common shares at a public offering price of $ 2.50 per share and the warrant. associated subscription. The warrants have an exercise price of $ 3.10 per share, are immediately exercisable and will expire three and a half years from the date of issue. The Company has granted the subscriber a 30-day option to purchase up to 2,100,000 additional common shares and / or additional warrants to purchase up to 2,100,000 common shares, at the public offering price per share per share. voucher, respectively, less subscription discounts and commissions.

HC Wainwright & Co. acts as the sole accounting manager of the offering.

Gross proceeds from the offering are expected to be $ 35 million, before deducting discounts and underwriting commissions and estimated offering costs and excluding the exercise of any warrants and warranties. option of the underwriter to purchase additional securities. This offer is expected to close on or around October 12, 2021, subject to the satisfaction of customary closing conditions.

A store registration statement on Form S-3 (File No. 333-236193) relating to the Offered Securities was filed with the United States Securities and Exchange Commission (the “SEC”) on January 31, 2020 and is entered into force on February 12. , 2020. The offer is being made only by means of a prospectus supplement and an accompanying prospectus which form part of the prior registration statement. A final prospectus supplement and accompanying prospectus relating to the public offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the Final Prospectus Supplement and accompanying prospectus may also be obtained, when available, by contacting HC Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by e-mail at placements@hcwco.com or by phone at (212) 856-5711.

This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty biopharmaceutical company focused on the development and commercialization of products targeting markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the ophthalmic subsidiary of the Company that supports UPNEEQ®.

Osmotica is present in the United States and Hungary.

Forward-looking statements

This press release includes statements which express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of the Company regarding future events or future results and are therefore or may be considered ” forward-looking statements ”. The actual results of the Company may differ materially from the results anticipated in these forward-looking statements, which can generally be identified by the use of forward-looking terminology, including the terms “believes”, “expects”, “may”. , “? “Should”, “research”, “projects”, “approximately”, “intention”, “plans”, “estimates” or “anticipates”, or, in each case, their negatives or other variations or a comparable terminology. These forward-looking statements include all matters that are not historical facts, such as statements regarding the closing of the offering. By their nature, forward-looking statements involve risks and uncertainties as they relate to events and depend on circumstances which may or may not occur in the future. The Company may not achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not significantly rely on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the Company’s forward-looking statements. Important factors that could cause actual results and events to differ materially from those indicated in forward-looking statements include market conditions and others, as well as the risks and uncertainties described in the “Risk Factors” section of the report. of the Company on Form 8-K, as filed with the Securities and Exchange Commission on September 8, 2021, under the heading “Risk Factors” included in the preliminary prospectus relating to the public offering filed with the Securities and Exchange Commission and other filings the Company makes with the Securities and Exchange Commission Foreign Exchange Commission. These forward-looking statements speak only at the time of this press release and the Company does not undertake to update or revise them publicly, whether as a result of new information, future events or otherwise, except if the law requires it.

Investor and Media Relations for Osmotica Pharmaceuticals plc

Lisa M. Wilson
Site Communications, Inc.
Phone. : 212-452-2793
E: lwilson@insitecony.com

About Catherine Sherrill

Check Also

Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28%

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us …

Leave a Reply

Your email address will not be published. Required fields are marked *